Legal Opinion
In Re Vioxx Products Liability Litigation
District Court, E.D. Louisiana
Decided July 3, 2007No. MDL 1657PublishedCited by 21 opinions
1Opinion of the Court
ORDER & REASONS
FALLON, District Judge.
Before the Court is Merck & Co., Inc.’s Motion for Summary Judgment (Rec.Doc. 5842) in two individual Vioxx cases on federal preemption grounds. The Court heard oral argument and took this motion under submission. Because the Court finds that the plaintiffs’ claims are not expressly nor impliedly preempted by virtue of the federal regulation of prescription drugs, Merck’s motion is now DENIED. 1
I. BACKGROUND
Vioxx, known generically as rofeeoxib, belongs to a general class of pain relievers known as non-steroidal anti-inflammatory drugs (“NSAIDs”). NSAIDs…
2Cases cited35 opinions
- Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 1984
- Skidmore v. Swift & Co.Supreme Court of the United States · 1944
- United States v. Mead Corp.Supreme Court of the United States · 2001
- Rice v. Santa Fe Elevator Corp.Supreme Court of the United States · 1947
- Auer v. RobbinsSupreme Court of the United States · 1997
30 more not listed; retrieve them via the Exa API.
3Cited by21 opinions
- McDarby v. Merck & Co., Inc.New Jersey Superior Court Appellate Division · 2008
- Knipe v. SmithKline BeechamDistrict Court, E.D. Pennsylvania · 2008
- Brockert v. WYETH PHARMACEUTICALS, INC., Texas Court of Appeals, 14th District (Houston)2009
- Horne v. Novartis Pharmaceuticals Corp.District Court, W.D. North Carolina · 2008
- Matthews v. Allstate InsuranceDistrict Court, E.D. Louisiana · 2010
16 more not listed; retrieve them via the Exa API.